What Is Claimed Is:

1. Use of pirfenidone in the manufacture of a medicament for the treatment of idiopathic pulmonary fibrosis (IPF), wherein the treatment comprises the dose of pirfenidone to be reduced in patients receiving an inhibitor of CYP1A2, wherein the inhibitor of CYP1A2 is fluvoxamine or enoxacin.

2. The use of claim 1 wherein the CYP1A2 inhibitor is fluvoxamine.

3. The use of claim 1 wherein the CYP1A2 inhibitor is enoxacin.

4. The use of claim 1 characterized in that the dose of pirfenidone is to be reduced by about 1600 mg/day, to a total daily dose of 800 mg/day or 801 mg/day.

5. The use of any one of claims 1-4 wherein pirfenidone is to be administered to the patient three times per day, with food.

6. Use of pirfenidone in the manufacture of a medicament for the treatment of idiopathic pulmonary fibrosis (IPF), wherein the treatment comprises the dose of pirfenidone to be reduced by about 1600 mg/day, to a total daily dose of 800 mg/day or 801 mg/day, in patients receiving an inhibitor of CYP1A2, wherein the inhibitor of CYP1A2 is fluvoxamine or enoxacin.

7. The use of claim 6 wherein the inhibitor of CYP1A2 is fluvoxamine.

8. The use of claim 1 wherein the inhibitor of CYP1A2 is enoxacin.

9. The use of any one of claims 6-8 wherein pirfenidone is to be administered to the patient three times per day, with food.

10. A package or kit for use in treating a patient in need of pirfenidone therapy, comprising (a) pirfenidone, optionally in a container, and (b) a package insert, package label, instructions or other labeling comprising reducing the dose of pirfenidone in patients receiving fluvoxamine or enoxacin.

11. A package or kit for use in treating a patient who has idiopathic pulmonary fibrosis (IPF), comprising (a) pirfenidone, optionally in a container, and (b) a package insert, package label, instructions or other labeling comprising reducing the dose of pirfenidone in patients receiving fluvoxamine or enoxacin.

12. The package or kit of claim 11 wherein the instructions or other labeling comprises reducing the dose of pirfenidone in patients receiving fluvoxamine.

13. The package or kit of claim 11 wherein the instructions or other labeling comprises reducing the dose of pirfenidone in patients receiving enoxacin.

14. The package or kit of claim 11 wherein the instructions or other labeling comprises reducing the dose of pirfenidone in patients receiving fluvoxamine and reducing the dose of pirfenidone in patients receiving enoxacin.

15. The package or kit of any one of claims 11 to 14 wherein the package insert, package label, instructions or other labeling comprises reducing the dose of pirfenidone by about 1600 mg/day, to a total daily dose of 800 mg/day or 801 mg/day.

16. The package or kit of any one of claims 11 to 15 wherein the package insert, package label, instructions or other labeling comprises administering pirfenidone to the patient three times per day, with food.